Basaksehir

Nasal obstruction caused by a deviated nasal septum is a common condition that can contribute to breathing difficulties and is linked to obstructive sleep apnea syndrome OSAS. Patients with nasal obstruction often breathe through their mouths during sleep, which may narrow the airway and increase the risk of sleep-related breathing problems. This study aims to determine how often difficult airway situations occur during septoplasty surgery and to identify factors that can predict such challenges, improving patient safety during anesthesia. The research is an observational prospective cohort study involving patients aged 18 to 65 undergoing septoplasty under general anesthesia due to nasal obstruction from a deviated septum. Standard anesthesia protocols will be followed, including specific medications and intubation procedures. Difficult intubation will be assessed using the Cormack-Lehane scale, with additional steps such as videolaryngoscope or laryngeal mask airway use if necessary. Preoperative assessments will include airway evaluation using the LEMON protocol and sleep apnea risk via the STOP-BANG questionnaire. Participants will undergo preoperative airway assessments and standard monitoring during surgery. Data on intubation difficulty, including number of attempts, use of tools like stylets, and airway management techniques, will be collected. The study will measure the airway difficulty using the Cormack-Lehane laryngeal view scale and track the success of intubation procedures. Participants safety will be monitored throughout, and no additional interventions beyond standard care will be administered. The study expects to complete by early 2027.

Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition affecting the peripheral nerves. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study aims to understand how well Imeroprubart works compared to placebo in treating CIDP. The study is sponsored by Immunovant Sciences GmbH and focuses specifically on adults meeting diagnostic criteria for typical or variant forms of CIDP. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The treatment period includes an initial 24-week phase Period 1 with Imeroprubart or placebo, followed by an extension to 52 weeks Period 2 for continued evaluation. Imeroprubart dosing is given once weekly via subcutaneous injection. Placebo is provided similarly during the first 24 weeks. During the study, participants will be monitored through clinical assessments including relapse status by Week 24, as well as measurements of disability, grip strength, muscle strength, and symptom scores. Electrodiagnostic tests support diagnosis at baseline. Safety and efficacy will be closely observed during treatment, with follow-up visits scheduled to assess outcomes. The total participation duration covers at least 24 weeks for the primary outcome assessment, with ongoing monitoring as defined by the study protocol.